ProCE Banner Activity

Expert Perspectives on Novel and Emerging HER2-Directed and TROP-2‒Targeted ADCs for Advanced Breast Cancer

Clinical Thought

In this engaging “Xtorial,” an expert interacts with healthcare professionals on the role of novel antibody‒drug conjugates in the management of patients with advanced breast cancer.

Released: May 02, 2024

Expiration: May 01, 2025

Share

Faculty

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini, Mersana, Merck, Myovant, Puma Technology, Seattle Genetics, Silicon Biosystems, Takeda.